Atropine sulfate 0.025% eye drops not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Anticholinergic; Cholinergic Muscarinic Antagonist FDA class
- Tested for
- Myopia Progression
- Main trialPhase 3
- “This clinical trial is designed to assess the efficacy and safety of Atropine Sulphate 0.025% w/v Eye Drops compared to placebo in a randomized, double-blind, placebo-controlled study for the management of myopia progression in children.”In the company’s words, NCT07329777 on ClinicalTrials.gov
- Other names
- Low dose atropine sulfate eye drops
Coming up1
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Sep 2027 | Atropine in the Treatment of Myopia Study in Malaysia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026